Skip to content
Screener

Reported August 11, 2025 · After market close

Revenue$518.0KBeat by $218.0K
EPS-$0.30Miss by $0.07
Revenue estimate$300.0K
EPS estimate-$0.23

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$215.1K
EPS estimate-$0.23

Financials

Q2 2025

Income statement

See full
Revenue$518.0K+398%
Gross profit$338.0K+369%
Operating income-$9.8M-112%
Net income-$9.7M-115%
EPS (diluted)-$0.30+16.7%

Balance sheet

See full
Cash & equivalents$24.3M+162%
Total debt$3.2M-9.4%
Total equity$1.1M-95.2%
Total assets$50.5M-32.4%

Cash flow

See full
Operating cash flow-$6.2M-3.3%
CapEx$349.0K+82.7%
Free cash flow-$6.5M-5.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$98.67M
Enterprise value$77.58M
P/S23.2×

Profitability

See full
Gross margin55.3%
Operating margin-1,498.3%-551pp
Net margin-1,489.7%-546pp
FCF margin-560.3%

Returns & leverage

See full
Return on equity-532.9%-717pp
Debt / equity2.9×+2.8×
Current ratio+2.7×

Segments

By geography

See full
Europe$24.0K
Asia Pacific--100%

FAQ

When did Insight Molecular Diagnostics Inc. report Q2 2025 earnings?
Insight Molecular Diagnostics Inc. (IMDX) reported Q2 2025 earnings on August 11, 2025 after market close.
What were Insight Molecular Diagnostics Inc.'s Q2 2025 revenue and EPS?
Insight Molecular Diagnostics Inc. reported revenue of $518.0K and eps of $-0.30 for Q2 2025.
Did Insight Molecular Diagnostics Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $300.0K by $218.0K. EPS missed the consensus estimate of $-0.23 by $0.07.
How did Insight Molecular Diagnostics Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 398.1% from $104.0K a year earlier and eps grew 16.7% from $-0.36.
Where can I find Insight Molecular Diagnostics Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001641172-25-022974) and the 10-Q periodic report (0000950170-25-106552) directly on SEC EDGAR. The filing index links above go to sec.gov.